Posted by: Northwest Eye in fuchs endothelial dystrophy on August 23, 2026
What Fuchs dystrophy does to the cornea
Fuchs endothelial corneal dystrophy (FECD) is a progressive disorder of the cornea’s inner cell layer, called the endothelium. This layer helps keep the cornea clear by regulating fluid. When it becomes damaged, your cornea may hold too much fluid and vision can change.
FECD involves loss of corneal endothelial cells, thickening of Descemet’s membrane, and deposits called guttae. As endothelial cells are lost, the cornea’s barrier and pump functions become less effective. Fluid can then build up, making the cornea swell, cloud, and scatter light. That change can reduce visual sharpness and create glare or halos.
FECD usually progresses slowly. One review describes the usual clinical course as 10–20 years, meaning the time over which the condition may develop and produce noticeable changes. Your course may not follow that exact pattern, so an eye examination matters more than a timeline alone.
Early FECD may cause no symptoms, and mild-to-moderate guttae can remain unchanged for years without affecting vision. As swelling increases, blur may be worse when you wake up because fluid collects in the cornea overnight and often clears during the day. Glare, halos, reduced visual sharpness, light sensitivity, and eye pain can also occur. In advanced FECD, swelling can extend into the cornea’s surface layer and cause fluid-filled blisters called bullae.
Who may develop Fuchs dystrophy and how it progresses
Fuchs dystrophy typically affects people over the age of 50, but signs and symptoms can begin in the fourth decade of life. Early-onset cases can occur earlier. Age alone cannot determine whether you have the condition or predict how it will affect your vision.
Fuchs dystrophy can occur sporadically or be inherited in an autosomal dominant pattern. That inheritance pattern means a changed gene can be passed from a parent to a child. The condition often runs in families, especially in early-onset cases, although having a family connection does not by itself establish a diagnosis.
Certain gene mutations, including mutations in the TCF4 gene, have been linked to FECD. Researchers also think genetic and environmental factors may interact. Oxidative stress and inflammation may play a role in endothelial-cell degeneration, but these associations do not identify a single cause for every person.
Fuchs dystrophy usually causes swelling in both corneas, although the two eyes may be affected differently. Endothelial-cell loss and guttae may build gradually, then reduce the cornea’s ability to control fluid. Because the eyes may not change at the same rate, compare symptoms only as a starting point and let examination findings guide the next step.
What vision changes can mean at different stages
Early Fuchs dystrophy may cause no noticeable symptoms. An eye examination may still show guttae before you notice a change in daily vision. Mild-to-moderate guttae can remain unchanged for years without affecting vision, so the absence of symptoms does not describe the full condition.
Moderate changes may appear as vision that is worse when you wake up and gradually improves during the day. Fluid builds up while your eyes are closed, then may clear as the day goes on. You may also notice glare, halos, light sensitivity, or reduced visual sharpness.
Swelling may reach the surface layer of the cornea and form bullae, which are fluid-filled blisters. If a blister ruptures, the exposed surface can be painful and should be treated as a corneal abrasion. Seek eye care rather than trying to manage that injury yourself.
Normal corneal endothelial cells decline at about 0.6% per year, meaning the usual yearly loss in a healthy cornea. That loss is faster in Fuchs dystrophy. The figure describes cell attrition, not a prediction of how quickly your vision will change, because symptoms also depend on the remaining cell function and the amount of swelling.
How an eye doctor checks for Fuchs dystrophy
Fuchs dystrophy is diagnosed clinically by an eye-care professional. The examination can include a slit-lamp view of the cornea, where early guttae may be visible. The doctor also looks for swelling, surface changes, bullae, scarring, and reduced vision as the condition progresses.
Pachymetry measures central corneal thickness. The cornea tends to become thicker as FECD worsens because endothelial-cell loss allows more fluid to collect. Repeating the measurement can help track change over time, but thickness is interpreted with the rest of the examination rather than used alone.
Specular microscopy is an imaging test used to assess the corneal endothelium. It works best when the cornea is clear and the endothelium is smooth, so diffuse or confluent guttae can limit the image. Confocal microscopy can image all corneal layers, including in advanced FECD, but it touches the eye and is more technically challenging.
Corneal endothelial cells do not regenerate in the usual way. Nearby cells spread into gaps left by lost cells, producing changes in cell size and shape that can be seen on microscopy. This helps explain why an examination may track cell patterns and corneal thickness even when your symptoms seem unchanged.
FECD testing can also help assess the risks of other eye surgery. If you are considering cataract surgery, ask your eye-care professional how your corneal thickness and endothelial-cell findings affect surgical planning.
What the eye measurements can show
A thickness measurement gives context about corneal swelling. For context, a normal, healthy cornea has a central thickness of 545 micrometers. That number is a reference point, not a diagnosis or a personal target. Your result must be interpreted with the appearance of the cornea, your endothelial findings, and your symptoms.
Endothelial-cell density describes how many functioning endothelial cells are present in a given area. For most adults over 40, average endothelial-cell density is between 2,000 and 3,000 cells per square millimeter. FECD can reduce that density, but a cell count may be difficult to obtain when guttae are widespread or the cornea is not clear.
Specular or confocal microscopy can help assess progression by showing endothelial-cell loss, guttae, and changes in the remaining cells. Scheimpflug tomography and corneal maps may also help assess disease and predict progression when swelling is not obvious during an examination. These tests answer different questions, so your doctor may use one or several depending on what the eye examination shows.
The practical purpose of these measurements is to connect structure with decisions. They can help distinguish a clear cornea that needs observation from a swollen cornea that needs symptom relief or a surgical discussion. They can also show when a test has limits, which is why no single number should determine treatment by itself.
When monitoring or symptom relief may be enough
If FECD is present but your cornea remains clear, treatment may not be needed. Monitoring may be the appropriate next step while vision remains good and the cornea is not decompensating. Treatment becomes necessary when corneal decompensation begins and good vision can no longer be preserved, so follow-up findings matter.
Hypertonic saline drops or ointment may relieve symptoms by drawing fluid out of the cornea. They may help early-morning blur and light sensitivity or pain caused by surface swelling. They cannot clear severe or posterior stromal swelling, so ongoing or worsening blur needs an eye-care assessment rather than repeated self-treatment.
Artificial tears and topical steroids are listed in one clinical source among treatments used for symptom relief and management of corneal swelling. A clinician should decide whether either option is appropriate for you. Do not start or reuse prescription eye drops without that direction, because the right treatment depends on the examination and the cause of your symptoms.
Cataract surgery planning may need to account for FECD. Corneal thickness and endothelial-cell findings can help assess the risks of other eye surgery. If you have both conditions, ask how the cornea may respond to surgery and whether the FECD findings change the order or type of treatment being discussed.
Symptom relief does not replace treatment for advanced corneal dysfunction. If the cornea becomes persistently swollen or vision and daily function decline, ask an eye-care professional whether a surgical option should enter the discussion.
Which surgical options doctors may discuss
When FECD causes advanced corneal dysfunction, corneal transplantation is the definitive treatment used to restore vision. Endothelial keratoplasty is the main surgical approach because it selectively replaces the dysfunctional inner layer rather than routinely replacing the full cornea. For symptomatic FECD, the commonly preferred partial-thickness options include DSAEK and DMEK.
DMEK and DSEK both address the corneal endothelium, but the choice depends on your eye’s anatomy and the surgical situation.
| Option | What it involves | Factors that may affect the choice |
|---|---|---|
| DMEK | Removes the affected Descemet membrane and endothelium and replaces them with donor Descemet membrane and endothelium. | It often provides faster recovery and sharper final vision in straightforward cases. |
| DSEK | Uses a partial-thickness endothelial transplant to replace dysfunctional inner corneal tissue. | It can be safer in certain complex eyes, depending on corneal shape, prior surgery, other eye conditions, and surgical experience. |
The choice between DMEK and DSEK depends on your corneal shape and thickness, previous eye surgery, other eye conditions, and the surgeon’s experience with each technique. Discuss those factors directly rather than choosing a procedure from its name or from a general recovery comparison. The appropriate action is to ask which option fits your eye anatomy and why.
Partial-thickness transplantation is used for advanced disease, while full-thickness transplantation may be selected when FECD causes corneal scarring or other complex disease. Penetrating keratoplasty is no longer the usual initial surgery because endothelial keratoplasty is less invasive and has lower complication rates. Full-thickness surgery may enter the conversation when severe swelling, scarring, bullous disease, or new blood vessels are present.
If FECD causes pain or reduces your daily function, discuss surgery with an eye-care professional. Bring your symptom pattern, prior eye-surgery history, and questions about recovery to that conversation so the recommendation can reflect your actual corneal findings.
What newer Fuchs treatments can and cannot promise
Descemet stripping only, also called DWEK or DSO, removes the affected Descemet membrane and endothelium without adding donor graft tissue. After cataract removal, deliberate central Descemet stripping may allow the central endothelium to repopulate in some people, but further studies are needed to validate that approach. It may benefit specific patients, not everyone with FECD.
Cell-based, drug-based, and other tissue-sparing approaches remain developing options rather than established replacements for transplantation. That distinction matters when you search for newer treatment information. A treatment under study may be scientifically promising without being appropriate, available, or established for routine care. Research reviews also discuss cultured endothelial-cell injections and synthetic corneal substitutes as emerging approaches. Those reviews identify donor shortages, variable outcomes, regulatory hurdles, and cost as challenges before these options enter routine use.
In 2026, a Phase 3 trial is testing whether topical ripasudil can protect eye cells after corneal transplant surgery. The trial tests a question; it does not establish ripasudil as standard care. Do not use a research treatment based on an online description or assume that participation would provide the same care as an established procedure.
Treatment choices depend on the condition of your cornea and the rest of your eye.
When to get urgent eye care
Seek immediate eye care for sudden severe pain, light sensitivity, redness, discharge, a white or gray spot, or rapid vision loss. These changes need prompt evaluation rather than watchful waiting, especially when they appear suddenly or together.
A ruptured bulla can cause severe pain and an open surface wound. Treat the situation as an eye-care problem because the wound should be treated as a corneal abrasion. Do not wait for ordinary morning blur to clear if pain or surface symptoms are severe.
Do not manage a suspected ruptured bulla at home with any of the following:
- An eye patch
- An unprescribed contact lens
- Leftover eye drops
Arrange immediate eye care instead. Use the warning signs above as the boundary between routine discussion and urgent evaluation.
Plan your next conversation with an eye-care professional
Your next eye-care conversation should connect your symptoms with the corneal findings. Before the visit, write down:
- Whether blur is worse when you wake up and improves during the day
- Glare, halos, light sensitivity, tearing, pain, or reduced vision
- Any sudden change, redness, discharge, white or gray spot, or rapid loss of vision
- Previous eye surgery and whether cataract surgery is being considered
- Any family history of Fuchs dystrophy
These details can help organize the discussion without replacing an examination.
Ask how your corneal thickness, endothelial-cell findings, and microscopy affect monitoring or treatment planning. If surgery is discussed, ask why DMEK, DSEK, another transplant approach, or continued monitoring fits your eye. A qualified eye-care professional decides individual suitability and treatment after examining you.
Use these questions to prepare for an eye-care visit with us at Northwest Eye in Minnetonka.
Questions to ask about Fuchs dystrophy
Does Fuchs endothelial dystrophy always need treatment?
No. If your cornea remains clear and vision is good, an eye-care professional may recommend monitoring rather than immediate treatment. Hypertonic saline may relieve some swelling-related symptoms, but it does not restore damaged endothelial cells or clear severe swelling. Treatment discussions change when corneal decompensation, persistent vision loss, pain, or reduced daily function develops.
Can Fuchs endothelial dystrophy run in families?
Yes. It may occur sporadically or follow an autosomal dominant inheritance pattern, especially in some early-onset cases. A family history does not confirm that you have the condition, but tell your eye-care professional about affected relatives. This information can help place your examination findings and symptoms in context.
Can cataract surgery be performed if I have Fuchs dystrophy?
Cataract surgery may be possible, but Fuchs findings can affect the planning and risk discussion. Your eye-care professional may consider corneal thickness, endothelial-cell findings, swelling, and other eye conditions before recommending an approach. Ask how the cornea may respond and whether the order or type of treatment should change.
Can eye drops cure Fuchs endothelial dystrophy?
No. Drops such as hypertonic saline may provide symptom relief by drawing fluid out of the cornea, but they cannot reverse endothelial-cell loss or clear severe swelling. Advanced corneal dysfunction may require endothelial keratoplasty or another surgical discussion. Do not start prescription drops or reuse leftover medication without clinical direction.
